hotspot -WSS

hotspot

author：explore 2025-10-03 00:07:17 - browse：26

Warning sign illustration made of 0s and 1s. -- first opinion coverage from sTAT — Adobe

Big businesses poised to profit from the advance of artificial intelligence in health care are pushing back against newly proposed federal rules meant to increase oversight and fairness of AI tools used to help make decisions about patient care.

The opposition, which includes Google and Amazon as well as large health care providers, insurers, and medical software vendors, is focused on an attempt to put tighter guardrails around the use of AI by the Office of the National Coordinator for Health Information Technology.

The agency wants to require developers of electronic health records and other health software to provide users with details about the training and testing of predictive models that draw data from their systems, or are hosted within them. It also wants developers to assess and publicly disclose potential risks and create a way for clinicians and other users to report problems.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： WuXi out of biotech trade group, U.S. and China relations to blame

knowledge

WSS

Ebola: Gilead Sciences antiviral shows promise as new treatment

How to save health care price transparency rules

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

eGenesis tests gene

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Wikipedia

hotspot

hotspot

Activists slam private health insurers over coverage restrictions

FDA clears AI tool for detecting skin cancer

How to save PrEP access — and even expand it

Independent physicians launch a new lobbying group

Malaria cases in Florida and Texas: Here’s what you need to know

Change Healthcare outage fallout shows need for new oversight

How one medical school became remarkably diverse

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Apple is now the first public company to be valued at $3 trillion

Biotech venture capitalists face new demands from investors

explore

Readout Newsletter: Merck, J&J, and long Covid

Why depression after traumatic brain injury is distinct

Why depression after traumatic brain injury is distinct

UCLA team creates talking throat patch for voice disorders

New brain studies show LSD's effects on the brain in full color

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

leisure time

focus

knowledge

Wikipedia